Raman Spectroscopic Studies on Screening of Myopathies

Myopathies are among the major causes of mortality in the world. There is no complete cure for this heterogeneous group of diseases, but a sensitive, specific, and fast diagnostic tool may improve therapy effectiveness. In this study, Raman spectroscopy is applied to discriminate between muscle mutants in Drosophila on the basis of associated changes at the molecular level. Raman spectra were collected from indirect flight muscles of mutants, <i>upheld¹</i> (<i>up¹</i>), <i>heldup²</i> (<i>hdp²</i>), <i>myosin heavy chain⁷</i> (<i>Mhc⁷</i>), <i>actin88F^KM88</i> (<i>Act88F^KM88</i>), <i>upheld¹⁰¹</i> (<i>up¹⁰¹</i>), and <i>Canton-S</i> (<i>CS</i>) control group, for both 2 and 12 days old flies. Difference spectra (mutant minus control) of all the mutants showed an increase in nucleic acid and β-sheet and/or random coil protein content along with a decrease in α-helix protein. Interestingly, the 12th day samples of <i>up¹</i> and <i> Act88F^KM88</i> showed significantly higher levels of glycogen and carotenoids than <i>CS</i>. A principal components based linear discriminant analysis classification model was developed based on multidimensional Raman spectra, which classified the mutants according to their pathophysiology and yielded an overall accuracy of 97% and 93% for 2 and 12 days old flies, respectively. The <i>up¹</i> and <i>Act88F^KM88</i> (nemaline-myopathy) mutants form a group that is clearly separated in a linear discriminant plane from <i>up¹⁰¹</i> and <i>hdp²</i> (cardiomyopathy) mutants. Notably, Raman spectra from a human sample with nemaline-myopathy formed a cluster with the corresponding Drosophila mutant (<i>up¹</i>). In conclusion, this is the first demonstration in which myopathies, despite their heterogeneity, were screened on the basis of biochemical differences using Raman spectroscopy